Assessing blood-based biomarkers to define a therapeutic window for natalizumab

Identifier:  imarina:9242332

Handle: https://hdl.handle.net/20.500.11797/imarina9242332

Authors:  Granell-Geli J; Izquierdo-Gracia C; Sellés-Rius A; Teniente-Serra A; Presas-Rodríguez S; Mansilla MJ; Brieva L; Sotoca J; Mañé-Martínez MA; Moral E; Bragado I; Goelz S; Martínez-Cáceres E; Ramo-Tello C

Abstract:
Natalizumab is a monoclonal antibody that binds CD49d. Although it is one of the most effective treatments for Relapsing-Remitting Multiple Sclerosis (RRMS), a dosing regimen has not been optimized for safety and efficacy in individual patients. We aimed to identify biomarkers to monitor Natalizumab treatment and to establish a personalized dose utilizing an ongoing longitudinal study in 29 RRMS patients under Natalizumab with standard interval dose (SD) of 300 mg/4 wks or extended interval dose (EID) of 300 mg/6 wks. Blood samples were analyzed by flow cytometry to determine CD49d saturation and expression in several T and B lymphocytes subpopulations. Each patient was analyzed at two different timepoints separated by 3 Natalizumab administrations. Natalizumab and sVCAM-1 levels in serum were also analyzed using ELISA. To determine the reproducibility of various markers, two different timepoints were compared and no significant differences were observed for CD49d expression nor for saturation; SD patients had higher saturation levels (~80%) than EID patients (~60%). A positive correlation exists between CD49d saturation and Natalizumab serum levels. CD49d expression and saturation are stable parameters that could be used as biomarkers in the immunomonitoring of Natalizumab treatment. Moreover, Natalizumab and sVCAM-1 serum levels could be used to optimize an individual’s dosing schedule. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.